However, only 20–40% of chronic hepatitis B (CHB) patients achieve HBeAg seroconversion after 48 weeks of IFN‐α treatment.[11] Thus, it would be beneficial to identify DNA sensors that recognize cccDNA and contribute to HBV inhibition in ways beyond IFN‐α. Here, IFNA1 is linked to chronic hepatitis B virus infection.